MX2023013487A - Células t reguladoras (treg) con receptor quimérico de antígeno específicas de antígeno inmunosupresoras para la prevención y/o tratamiento de trastornos autoinmunes y aloinmunes. - Google Patents

Células t reguladoras (treg) con receptor quimérico de antígeno específicas de antígeno inmunosupresoras para la prevención y/o tratamiento de trastornos autoinmunes y aloinmunes.

Info

Publication number
MX2023013487A
MX2023013487A MX2023013487A MX2023013487A MX2023013487A MX 2023013487 A MX2023013487 A MX 2023013487A MX 2023013487 A MX2023013487 A MX 2023013487A MX 2023013487 A MX2023013487 A MX 2023013487A MX 2023013487 A MX2023013487 A MX 2023013487A
Authority
MX
Mexico
Prior art keywords
cells
treg
immunosuppressive
autoimmune
regulatory
Prior art date
Application number
MX2023013487A
Other languages
English (en)
Spanish (es)
Inventor
Juan C Jaume
Shahnawaz Imam
Original Assignee
Univ Toledo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Toledo filed Critical Univ Toledo
Publication of MX2023013487A publication Critical patent/MX2023013487A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023013487A 2021-05-14 2022-05-10 Células t reguladoras (treg) con receptor quimérico de antígeno específicas de antígeno inmunosupresoras para la prevención y/o tratamiento de trastornos autoinmunes y aloinmunes. MX2023013487A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/320,663 US11766457B2 (en) 2021-05-14 2021-05-14 Immunosuppressive antigen-specific chimeric antigen receptor Treg cells for prevention and/or treatment of autoimmune and alloimmune disorders
PCT/US2022/028454 WO2022240797A1 (en) 2021-05-14 2022-05-10 Immunosuppressive antigen-specific chimeric antigen receptor treg cells for prevention and/or treatment of autoimmune and alloimmune disorders

Publications (1)

Publication Number Publication Date
MX2023013487A true MX2023013487A (es) 2024-02-28

Family

ID=83999123

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013487A MX2023013487A (es) 2021-05-14 2022-05-10 Células t reguladoras (treg) con receptor quimérico de antígeno específicas de antígeno inmunosupresoras para la prevención y/o tratamiento de trastornos autoinmunes y aloinmunes.

Country Status (9)

Country Link
US (3) US11766457B2 (enExample)
EP (1) EP4340895A4 (enExample)
JP (1) JP2024518826A (enExample)
KR (1) KR20240007197A (enExample)
CN (1) CN117580594A (enExample)
AU (1) AU2022272620A1 (enExample)
CA (1) CA3218583A1 (enExample)
MX (1) MX2023013487A (enExample)
WO (1) WO2022240797A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4434539A1 (en) * 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024194355A1 (en) * 2023-03-20 2024-09-26 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2026010984A1 (en) * 2024-07-01 2026-01-08 The University Of Toledo Islet antigen-specific car-t therapy
WO2026008994A1 (en) 2024-07-04 2026-01-08 Quell Therapeutics Limited Expression construct

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016174652A1 (en) 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
JP7123794B2 (ja) * 2015-12-09 2022-08-23 メモリアル スローン ケタリング キャンサー センター 免疫細胞組成物及びそれを使用する方法
AU2019377867B2 (en) * 2018-11-08 2026-03-12 The University Of Toledo Immunosuppressive antigen-specific chimeric antigen receptor treg cells for prevention and/or treatment of autoimmune and alloimmune disorders
EP3911371A4 (en) 2019-01-18 2023-04-26 University of Southern California METHODS AND COMPOSITIONS FOR IMPROVING THE SAFETY AND EFFICACY OF CELL THERAPY
AU2020322221A1 (en) * 2019-07-26 2022-03-24 Janssen Biotech, Inc. Anti-hK2 chimeric antigen receptor (CAR)

Also Published As

Publication number Publication date
AU2022272620A9 (en) 2023-11-30
US12144829B2 (en) 2024-11-19
CN117580594A (zh) 2024-02-20
KR20240007197A (ko) 2024-01-16
EP4340895A1 (en) 2024-03-27
EP4340895A4 (en) 2025-04-16
US20220362294A1 (en) 2022-11-17
AU2022272620A1 (en) 2023-11-23
US20240100094A1 (en) 2024-03-28
JP2024518826A (ja) 2024-05-07
US20250059252A1 (en) 2025-02-20
CA3218583A1 (en) 2022-11-17
WO2022240797A1 (en) 2022-11-17
US11766457B2 (en) 2023-09-26

Similar Documents

Publication Publication Date Title
MX2023013487A (es) Células t reguladoras (treg) con receptor quimérico de antígeno específicas de antígeno inmunosupresoras para la prevención y/o tratamiento de trastornos autoinmunes y aloinmunes.
Sbodio et al. Redox mechanisms in neurodegeneration: from disease outcomes to therapeutic opportunities
Jackson Reactive oxygen species in sarcopenia: Should we focus on excess oxidative damage or defective redox signalling?
Wang et al. Inhibitory zinc-enriched terminals in the mouse cerebellum: double-immunohistochemistry for zinc transporter 3 and glutamate decarboxylase
AU2022202797A1 (en) Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
Agrawal et al. A novel anti-EMMPRIN function-blocking antibody reduces T cell proliferation and neurotoxicity: relevance to multiple sclerosis
Paz et al. Focal cortical infarcts alter intrinsic excitability and synaptic excitation in the reticular thalamic nucleus
Meister et al. Dickkopf-3, a tissue-derived modulator of local T-cell responses
ZA202204777B (en) Novel combinations for antigen based therapy
BR112018076263A2 (pt) composições e métodos para a depleção de células
MX2023001287A (es) Bancos universales de células t específicas de antígeno y métodos de fabricación y uso terapéutico de los mismos.
Muir Clinical trial design for stem cell therapies in stroke: What have we learned?
CO2022017087A2 (es) Péptidos y métodos para el tratamiento de esclerosis múltiple
Meulders et al. Lipotoxicity and oocyte quality in mammals: pathogenesis, consequences, and reversibility
MX2022010280A (es) Metodos y composiciones para modular las concentraciones de arginina en celulas inmunitarias.
Urrutia et al. Overexpression of Glutamate Decarboxylase in mesenchymal stem cells enhances their immunosuppressive properties and increases GABA and nitric oxide levels
Mejia-Carmona et al. Evaluation of antioxidant enzymes in response to predator odor stress in prefrontal cortex and amygdala
Saraceno et al. Effects of perinatal asphyxia on rat striatal cytoskeleton
Kuo et al. The combination of peripheral nerve grafts and acidic fibroblast growth factor enhances arginase I and polyamine spermine expression in transected rat spinal cords
Tuji et al. Ultrastructural assessment of the radioprotective effects of sodium selenite on parotid glands in rats
BR112021018684A2 (pt) Métodos para aumentar a eficiência de esgotamento de células tcr¿¿+
Rakgantsho et al. Acetylcholine receptor agonist effect on seizure activity and GABAergic mechanisms involved in prolonged febrile seizure development in an animal model
A LoCascio et al. Hematopoietic stem cell transplantation for the treatment of autoimmunity in type 1 diabetes
Ichikawa et al. Calretinin-immunoreactivity in trigeminal neurons innervating the nasal mucosa of the rat
Gallaher et al. Recovery of viscerosensory innervation from the dorsal root ganglia of the adult rat following capsaicin‐induced injury